Combined RNA interference of adenine nucleotide translocase-2 and ganciclovir therapy in hepatocellular carcinoma

详细信息    查看全文

• 作者：Jung Eun Kim ; Mi-Hye Hwang ; Ho Won Lee ; Sang-Woo Lee ; Jaetae Lee ; Byeong-Cheol Ahn
• 关键词：Huh 7/hNIS-HSV1-sr39tk-EGFP ; Huh 7/human sodium iodide symporter gene-Herpes simplex virus-sr39 thymidine kinase-green fluorescence protein ; Huh 7/NTG cells ; Huh 7/human sodium iodide symporter gene ; HSV1-sr39 thymidine kinase ; enhanced green fluorescence protein
• 刊名：Nuclear Medicine and Biology
• 出版年：November, 2013
• 年：2013
• 卷：40
• 期：8
• 页码：987-993
• 全文大小：1111 K

文摘

Purpose

The purpose of this study was to investigate the anticancer effects of combined RNA interference (RNAi) of the adenine nucleotide translocase-2 (ANT2) gene and ganciclovir (GCV) therapy for treatment of hepatocellular carcinoma cells (Huh 7) in an animal model.

Methods

The Huh 7/NTG stable cell line was established by transfection of a vector with the human sodium iodide symporter (hNIS), HSV1-sr39 thymidine kinase (tk), and enhanced green florescent protein (EGFP) fusion gene into Huh 7 cells. mRNA expressions of these genes were evaluated by RT-PCR analysis. The functions of hNIS and HSV1-sr39tk were verified with ¹²⁵I uptake and ³H-penciclovir (PCV) uptake tests. EGFP and hNIS expression was confirmed with confocal microscopy after immunocytochemical staining. We treated the tumor cells with ANT2 shRNA or GCV or both ANT2 shRNA and GCV and treated the in vivo mouse model with a Huh 7/NTG tumor xenograft. The therapeutic effects of the in vivo study were assessed with caliper measurements and gamma camera imaging using ^99mTc-pertechnetate.

Results

Huh 7/NTG cells showed a cell number-dependent increase in ¹²⁵I uptake and a 24-fold higher ³H-PCV uptake compared to parent Huh 7 cells. Huh 7/NTG cells transfected with ANT2 shRNA had lower ANT2 mRNA expression and more impaired proliferation activity than cells transfected with scramble shRNA. Proliferation of Huh 7/NTG cells was also inhibited by GCV treatment. Combined GCV and ANT2 shRNA therapy further inhibited cell proliferation in the in vitro study. The combined therapy with GCV and ANT2 shRNA showed a further decrease in tumor growth in the mouse model.

Conclusions

Our results suggest that the combined RNA interference with ANT2 and GCV therapy inhibited hepatocellular carcinoma cell proliferation more than single GCV therapy or ANT2 shRNA therapy in vitro and in vivo. Therefore it could be applied treating incurable hepatocellular carcinoma.